A Open-Label Extension Study of the Long-Term Safety and Efficacy of Rosiglitazone Extended-Release (RSG XR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects With Mild-to-Moderate Alzheimer's Disease (REFLECT-4).

Trial Profile

A Open-Label Extension Study of the Long-Term Safety and Efficacy of Rosiglitazone Extended-Release (RSG XR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects With Mild-to-Moderate Alzheimer's Disease (REFLECT-4).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms REFLECT-4
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Jan 2011 Additional trial locations identified as reported by ClinicalTrials.gov.
    • 03 Feb 2010 New source identified and integrated (Clinical Trials Registry - India record no. CTRI2009-091-000497).
    • 09 Jun 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top